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Abstract
Background: The risk of acquisition of antibiotic resistant-bacteria during or shortly after antibiotic therapy is still
unclear and it is often confounded by scarce data on antibiotic usage.
Primary objective of the study is to compare rates of acquisition of methicillin-resistant Staphylococcus aureus and
extended spectrum beta-lactamase-producing Enterobacteriaceae in hospitalised patients, after starting antibiotic
therapy.
Methods/Design: The study, running in three European hospitals, is a multicenter, prospective, longitudinal,
observational cohort study funded from the European Community’s Seventh Framework Programme [FP7/2007-
2013] within the project ‘Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt
bacteria’ (acronym SATURN). Nasal and rectal screening for methicillin-resistant Staphylococcus aureus and extended
spectrum beta-lactamase-producing Enterobacteriaceae will be obtained at hospital admission, discharge, at
antibiotic start (t0, within one hour) and at the following intervals: day 3 (t1), 7 (t2), 15 (t3), and 30 (t4). Two nested
case-control studies will be performed. The objective of the first study will be to define individual level of risk
related to specific antibiotics. Patients acquiring methicillin-resistant Staphylococcus aureus and extended spectrum
beta-lactamase-producing Enterobacteriaceae (cases) will be compared with patients not acquiring antibiotic-
resistant strains after starting antibiotic therapy (controls; ratio 1:4). To define the impact of antibiotics on new
acquisition of target antibiotic-resistant bacteria, a second nested case-control study will be done (ratio 1:4). Control
group will be selected among patients not receiving antibiotics, admitted in the same ward on the day of the
corresponding case, with negative cultures at admission. Epidemiological, clinical and microbiological data will be
prospective collected.
Discussion: The rationale of this study is to better understand the impact of antibiotic use on acquisition, selection
and transmission of antimicrobial resistant-bacteria in European hospitals.
Trial registration: ClinicalTrials.gov NCT01208519.
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Despite many efforts, the control of nosocomial antibiotic-
resistant infections is still a permanent and unresolved
issue in healthcare institutions worldwide facing increased
morbidity, mortality and hospital costs [1-3]. Selective
pressure exerted by antibiotics plays a central role on the
acquisition, selection, persistence and transmission of
resistant pathogens which may include the following
effects: (1) eradication of the susceptible skin and gut flora
will increase the likelihood of acquisition of antibiotic-
resistant organisms, especially in settings with endemic
resistance; (2) antibiotics select for pre-existing antibiotic-
resistant bacteria (ARB) in carriers and enhance the likeli-
hood of spread; (3) antibiotic selection pressure may trans-
form low-level carriers to high-level spreaders; (4)
antibiotics active against antibiotic-susceptible bacteria
may convert carriers of susceptible bacteria to non-car-
riers, indirectly promoting acquisition and spread of ARB;
(5) antibiotic exposure may increase the risk of endogen-
ous infection with ARB related to changes in colonisation
resistance and bacterial virulence at the individual host
level [4]. Numerous papers demonstrated that prior anti-
microbial drug exposure is a strong risk factor for coloni-
sation and infection due to a drug resistant pathogen [5,6].
A meta-analysis that included 76 studies for a total of
24,230 patients documented that the risk of acquiring
methicillin-resistant Staphylococcus aureus (MRSA) was
increased by 1.8-fold in patients who had taken antibiotics.
Antibiotic exposure was determined in the 126 days pre-
ceding MRSA isolation [7]. Such risk was almost 3-fold
greater after using quinolones or glycopeptides and 2-fold
for cephalosporins. A multicentre prospective cohort
study conducted in several Italian hospitals showed that
5% of patients were newly colonised by ARB including
MRSA in nasal samples, after starting antibiotic therapy.
Nine percent of those patients developed an infection by
the same strain over the 30-day follow-up. The use of car-
bapenems was associated with the highest incidence of
colonisation with eight new cases of MRSA colonisation
for 1,000 antibiotic-day [4].
The likelihood of acquisition of nosocomial ARB dur-
ing or shortly after therapy with different antibiotic
agents is still unclear and is often confounded by scarce
data on antibiotic usage at the individual patient level.
Study design, selection bias, definition of control groups
and failure to control for confounding variables might
account for conflicting results [8]. No prospective multi-
centre cohort study has been conducted defining, in
countries with varying baseline antimicrobial resistance
rates, the impact of antibiotic exposure on the develop-
ment and acquisition of nosocomial carriage by ARB,
after accounting for individual and group-level con-
founding variables, such as case-mix and colonisation
pressure [8-10].
Presentation of the hypothesis
We designed a 2-year observational cohort study
(WorkPackage 4 of the EU-funded SATURN project) in
order to clarify and determine the role of antibiotic
therapy in the acquisition of ARB in hospitalized
patients. The study will run in three European hospitals,
ranging from 700 to 3,500-bed capacity: Università Cat-
tolica Sacro Cuore “Policlinico A. Gemelli” (UCSC,
Rome, Italy), Institute of Infectious Diseases “Matei
Bals” (IDMB, Bucharest, Romania), and Clinical Center
of Serbia (CCS, Belgrade, Serbia). Overall, 6 medical and
6 surgical wards will be included. All centers obtained
ethical approval from the local institution review board.
Testing the hypothesis
All adult patients (> 18 years) starting intravenous and/
or oral antibiotic treatments during hospitalisation will
be included in the study. Written informed consent will
be obtained by every patient before study inclusion.
Exclusion criteria will be pregnancy and recent nose
surgery. Patients starting antibiotic therapy per os and/
or intravenously will be sampled at antibiotic start (t0,
within one hour) and at the following intervals: day 3
(t1), 7 (t2), 15 (t3), 30 (t4) (Figure 1). Patients colonised
with MRSA and/or extended-spectrum b-lactamase
(ESBL)-producing gram-negative bacteria before starting
antibiotic therapy (t0 sample) will be excluded from fol-
low-up cultures and analysis. Patients will be followed
during the hospitalisation and afterwards for a total of
30-day from the inclusion in the study. Screening will
be performed in outpatient clinics after patients’ dis-
charge from the hospital, if possible.
Outcomes
The primary outcome will be the rate of acquisition of
target antibiotic bacteria by 1,000 antibiotic-days in hos-
pitalised patients. The rate will be also defined accord-
ing to antibiotic class and single drug. Patients will be
stratified by class of risk (e.g., cirrhosis, diabetes, malig-
nancies) and rate of acquisition will be defined. The sec-
ondary outcome will be the rate of nosocomial
infections by 1,000 days of hospitalisation in newly colo-
nised patients after undergoing antibiotic therapy.
Variables
The following variables will be identified in cases and
controls: age; gender; reason for admission; inter and
intra-wards transfers; admission from home or other
acute or long-term care institutions; previous hospitali-
sation; surgical procedures; Intensive Care Unit (ICU)
stay (previous 12 months); residency in long-term care
facility; transfer form another hospital; nursing and/or
medical domiciliary assistance; urinary catheter; central
venous catheter (CVC, at hospital admission);
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Chronic Disease Score, CDS-ID); room sharing with a
ESBL or MRSA patient; previous MRSA or ESBL carrier;
consciousness at admission; antibiotic therapy (previous
30 days).
Antibiotic therapy will be reported as for daily dosage,
frequency of dosage(s), route of administration, type of
antibiotic(s), reason for starting and stopping, duration
of therapy. At every clinical follow-up the following vari-
ables will be also detected: presence of urinary catheters;
Figure 1 Work flow of the SATURN WP4 clinical protocol.
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tive patient; MRSA or ESBL-producing gram-negative
infections (including type of infection, therapy, and out-
come); albumin, creatinine and blood urea nitrogen
levels.
Microbiological methods
Methicillin resistance detection in Staphylococcus aureus
Dedicated personnel will be trained in performing nasal
samples. Both nostrils will be sampled. Specimens
obtained with a dry swab (Copan, Italy) will be incu-
bated overnight in 2 ml of Mueller-Hinton broth sup-
plemented with colistin 32 μg/mL and 2.5% NaCl (CS)
at 35°C in room air. Then 10 μl of broth sample will be
plated onto chromogenic medium (MRSAid, bioMér-
ieux, Marcy l’Étoile, France) [11] and will be incubated
overnight (18-24 h) at 35°C. The growth of > 1 colonies
will indicate methicillin-resistance. The isolation of S.
aureus will be confirmed through the use of a classical
DNase assay or automated phenotypic methods
(VITEK2, bioMérieux, Marcy l’Étoile, France, or Phoe-
nixTM, Becton Dickinson, Burlington, NC) [12]. Oxacil-
lin-resistant colonies will be isolated and stored in
Trypticase Soy Broth (Becton Dickinson, Burlington,
NC) and glycerol 20% at -80°C in freezer vials.
Extended spectrum beta-lactamases detection in
Enterobacteriaceae
Rectal specimens will be obtained with a dry swab
(Copan, Italy) and will be inoculated onto plates of
ESBL chromogenic medium (Brillaince ESBL, Oxoid,
Basingstoke, UK). After the direct plating, 1 ml of trypti-
case soy broth (TSB) with 0.5% NaCl will be added to
the transport tube and the selective broth will be incu-
bated overnight at 37°C in air. The selective medium
will be plated on the ESBL chromogenic medium fol-
lowing the same procedure as for direct plating. Colo-
nies will be identified according to manufacturers’
recommendations and subcultured for confirmatory
testing. The ESBL phenotype of identified colonies of
Klebsiella species, Escherichia coli and Proteus species
will be detected by confirmatory double disk diffusion
test (DDT). Ceftazidime (30 μg), cefotaxime (30 μg), or
cefepime (30 μg) discs will be placed on Mueller-Hinton
agar plates, 20 mm apart (centre to centre) from a cla-
vulanate disc (clavulanic acid 10 μg). The test will be
considered as positive when a decreased susceptibility to
cefotaxime is combined with a clear-cut enhancement of
the inhibition zone of cefotaxime in front of the clavula-
nate-containing disk, often resulting in a characteristic
shape-zone referred to as ‘champagne-cork’ or ‘keyhole’
[12,13]. Plates will be incubated overnight (18-20 h) at
35°C. ESBL-producing bacteria will be stored in micro-
banks (Pro-Lab Diagnostic, Canada) at -80°C.
Statistical analysis
The assessable population for each target organism will
include all treated patients from whom baseline screen-
ing and at least one follow-up screening will be avail-
able. The incidence of colonisation will be defined by
the number of new cases of colonisation for 1,000 days
of antibiotic therapy. Only patients with a negative base-
line (t0) will be included in the longitudinal analysis.
The length of exposure to antibiotic therapy for patients
newly colonised by ARB will be defined by the number
of days between the inclusion in the study and the date
of the first positive sample. The length of exposure to
antibiotic therapy for patients not colonised will be
defined by the number of days between the inclusion in
the study and the date of antibiotic discontinuation. The
colonisation pressure will be calculated for each center
and defined as the average point of prevalence for anti-
biotic-resistant bacteria for all days until acquisition or
discharge. Time-to-event analysis (in days) between the
inclusion in the study and the acquisition of colonisa-
tion will be done using Kaplan-Meier curves and Cox
proportional hazard regression modeling in which the
number of days until acquisition will be the dependent
variable. Two nested case-control studies will be
performed:
Case control study 1
To define the impact of antibiotics on new acquisition
of MRSA and ESBL-producing Enterobacteriaceae,a
matched case-control study will be done (ratio 1:4). The
control group will be selected among patients not
receiving antibiotics, admitted in the same ward on the
day of the corresponding case, with negative cultures at
hospital admission. Matching criteria will include: age (±
5 years), sex, and total length of hospitalisation.
Case control study 2
To define individual level of risk related to specific anti-
biotics, patients acquiringM R S Aa n dE S B L - p r o d u c i n g
Enterobacteriaceae will be compared with patients not
acquiring ARB after starting antibiotic therapy (ratio
1:4). Previously known risk factors or clinically relevant
significant variables from the univariate analysis will be
considered for inclusion in multivariate logistic regres-
sion analysis. The Hosmer and Lemeshow goodness-of-
fit test will be used to assess model fit.
Sample size
Since the rate of acquisition of ESBL-producing gram-
negative bacteria in patients receiving antibiotic therapy
has not been established in prospective cohort studies,
prevalence proportion was derived from retrospective
case-control studies and defined as 5%. Sample size cal-
culation for the rate of new acquisition of MRSA has
been derived by a previous study where the acquisition
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able to analyse 257 patients newly colonised by MRSA
and 443 by ESBL-producing gram-negative, 8565
patients starting antibiotic therapy need to be enrolled.
According to the number of hospital admission/year
and percentage of patients starting antibiotic in each
ward, the clinical centers are required to provide the fol-
lowing numbers of patients with new colonisation by
MRSA/ESBL Enterobacteriaceae: 48/95, 121/201, and
88/147 for UCSC, IDMB, CCS, respectively.
Implications of the hypothesis
SATURN project is a European multicentre study that
aims to provide an in-depth knowledge of ARB acquisi-
tion through the analysis of antibiotic classes, duration
of treatment and dosage in the nosocomial setting by a
multidisciplinary approach. The SATURN project web-
site http://www.saturn-project.eu provides the informa-
tion and details concerning the different WPs and the
entire project.
Several outcomes will be obtained at the end of the
study (December 2014, expected): the rate of acquisition
of target ARB by 1,000 antibiotic-days according to dif-
ferent classes of antibiotics, duration of therapy, and
antibiotic combinations (monotherapy versus combina-
tions); risk factors associated with new colonisation by
target ARB; and risks for nosocomial infections due to
target ARB after a cycle of antibiotic therapy adjusted
by length of hospitalisation and ward colonisation
pressure.
The WP4 study is currently recruiting patients in all
clinical centers. The accomplishment of the study will
be pursued thanks to the great strive of all clinicians,
nurses and microbiology staff in every study step. An
advertising campaign (posters, stickers and pictures) was
performed in the selected wards in order to thrill and
sensitise the recruited staff.
The results of the study should lead to the design of
specific infection control measures for preventing spread
of ARB in hospitalised non-ICU patients undergoing
antibiotic therapy. A potential benefit for selective
screening in high-risk patients during antibiotic therapy
or shorter duration of antibiotics in such patients might
be hypothesised. Readily available colonisation informa-
tion could impact empiric therapy for nosocomial infec-
tions or, for example, the potential need of mupirocin
prophylaxis for patients colonised by MRSA during hos-
pitalisation. Assessment of the usefulness of the recom-
mendations derived from the results of the SATURN
study should be of valuable help for those in charge of
infection control, for hospital administrators, and for
those managing budgets of large healthcare organisations.
We do expect that SATURN project results will have
a direct impact on clinical practice, improving the
appropriateness of antibiotic prescribing policy, the pre-
vention of antibiotic-resistant infections and the heigh-
tener of patients’ quality care.
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